Skye Bioscience Partners with Halozyme to Develop Nimacimab for Obesity Treatment

Skye Bioscience Partners with Halozyme to Advance Obesity Treatment

Skye Bioscience, Inc. has entered into a significant collaboration with Halozyme Therapeutics, Inc. to leverage the latter’s ENHANZE® drug delivery technology for developing a subcutaneous formulation of nimacimab, specifically aimed at treating obesity. Announced on December 2025, this non-exclusive global partnership allows Skye to explore higher dosages of nimacimab by utilizing larger injection volumes, which is expected to enhance the drug's therapeutic effectiveness. This collaboration marks a pivotal step for Skye, as it seeks to address the burgeoning obesity epidemic through innovative treatment methods.

Dr. Helen Torley, CEO of Halozyme, expresses enthusiasm about how this agreement expands the application of their ENHANZE technology within the growing obesity market, reflecting their commitment to sustainable growth through strategic collaborations. The partnership is poised to enable Skye to rigorously assess the potential of nimacimab through higher dosing strategies, including possible combinations with GLP-1 receptor agonists. This multifaceted approach not only enhances the therapeutic landscape for obesity treatment but also underscores the increasing demand for effective solutions in managing weight-related health issues.

Skye’s CEO, Punit Dhillon, emphasizes the necessity of exploring subcutaneous higher doses of nimacimab for a comprehensive evaluation of its efficacy in combating obesity. The collaboration includes milestone payments tied to successful development and commercialization, while Halozyme will receive mid-single-digit royalties on the net sales of the nimacimab formulation for at least a decade. With plans to initiate a Phase 2b clinical trial in mid-2026, the partnership is set to evaluate the efficacy of nimacimab alongside GLP-1 receptor agonists, positioning Skye at the forefront of innovative obesity treatments.

In related news, Skye Bioscience faces a class action lawsuit initiated by The Gross Law Firm, which alleges that the company made misleading statements regarding nimacimab’s effectiveness. Shareholders who purchased shares between November 4, 2024, and October 3, 2025, are encouraged to consider a lead plaintiff appointment in the case. The law firm emphasizes the importance of registering before the January 16, 2026 deadline, providing potential participants with updates on the case's progress.

The Gross Law Firm is dedicated to protecting investors’ rights and aims to ensure accountability in corporate practices. They offer assistance to affected shareholders, highlighting that joining the lawsuit carries no costs or obligations, thus encouraging those impacted to seek recourse for any misleading corporate conduct.